Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms

被引:0
|
作者
Joseph Golec
John A. Vernon
机构
[1] University of Connecticut,Finance Department, School of Business
[2] University of North Carolina at Chapel Hill,Department of Health Policy and Management
[3] National Bureau of Economic Research (NBER),undefined
来源
PharmacoEconomics | 2010年 / 28卷
关键词
Stock Return; Price Regulation; Price Control; Price Inflation; Pharmaceutical Firm;
D O I
暂无
中图分类号
学科分类号
摘要
EU countries closely regulate pharmaceutical prices, whereas theUS does not.
引用
收藏
页码:615 / 628
页数:13
相关论文
共 4 条
  • [1] Measuring US Pharmaceutical Industry R&D Spending
    Joseph Golec
    John Vernon
    PharmacoEconomics, 2008, 26 : 1005 - 1017
  • [2] Examining the link between price regulation and pharmaceutical R&D investment
    Vernon, JA
    HEALTH ECONOMICS, 2005, 14 (01) : 1 - 16
  • [3] The Dynamics of Pharmaceutical Regulation and R&D Investments
    Levaggi, Rosella
    Moretto, Michele
    Pertile, Paolo
    JOURNAL OF PUBLIC ECONOMIC THEORY, 2017, 19 (01) : 121 - 141
  • [4] PATENT LENGTH AND PRICE REGULATION IN AN R&D GROWTH MODEL WITH MONOPOLISTIC COMPETITION
    Zeng, Jinli
    Zhang, Jie
    Fung, Michael Ka-Yiu
    MACROECONOMIC DYNAMICS, 2014, 18 (01) : 1 - 22